



## A RETROSPECTIVE INVESTIGATION OF THE EFFICACY OF INTRAVITREAL CONBERCEPT INJECTIONS IN NON-PROLIFERATIVE DIABETIC RETINOPATHY

Dr Bala N, Dr Minakshi Mitra \*

Assistant Professor, Department of Physiology, Gouri Devi Institute of Medical Sciences and Hospital, Durgapur, West Bengal India.

### ABSTRACT

To date, few effective treatments have been offered. Pan retinal photocoagulation is the preferred treatment option for the treatment of critical NPDR. This approach, however, will maintain visual acuity only and could be interfere with other sight skills (such as ability to drive); also, the assessment of recurrence after therapy maintains huge. As a result, the development of local NPDR therapy is important to prevent the disease from progressing to a point where it may have a significant impact on visual acuity. The purpose of this study was to determine how intravitreal conbercept injections work in non-proliferative diabetic retinopathy. The study included patients with type 2 diabetes, medication-controlled blood sugar levels, glycosylated haemoglobin levels below 10 percent, then bp below 160/90 mmHg, respectively. The research comprised a total of 54 individuals with NPDR (26 men and 28 women; mean age, 60.1 8.3 years). A total of 54 eyes were chosen from the 54 patients, including 30 right eyes and 24 left eyes. The baseline patient characteristics are shown in Table 1. At baseline, the mean BCVA was 0.71 0.20 logMAR, and the mean CFT was 424.26 64.89. For diabetic retinopathy, anti-VEGF medication has lately become a prominent therapeutic choice. Anti-VEGF injections into the eyes have been used to treat 22 vision-threatening diseases. 23 This vision-saving procedure is especially beneficial to patients with diabetic retinopathy. In afflicted individuals, intravitreal conbercept injection exhibited a clear and persistent therapeutic effect on NPDR, according to our data. However, a more thorough investigation of the therapeutic mechanism is needed.

**Key words:** Conbercept, Patient Characteristics, Diabetic Retinopathy.

### INTRODUCTION

Diabetes mellitus has a high global prevalence<sup>1</sup>, then its problems are many and varied, which includes diabetic retinopathy, diabetes-related cardiovascular disease [1], diabetic nephropathy [2], and diabetic nephropathy. [3,4] Those issues are the leading cause of disorder and death in patients with diabetes, and they may be avoided. [5] Diabetic retinopathy is a frequent microvascular complication of diabetes [6], and it is caused by a high glucose metabolic stress condition.

Diabetic retinopathy is considered as a severe concern to mankind health since it has the potential to cause some degree of blindness. [7]

The two clinical phases of diabetic retinopathy are NPDR (non-proliferative diabetic retinopathy) and PDR (proliferative diabetic retinopathy). [8] Non-proliferative diabetic retinopathy (NPDR) is the first part of diabetes retinopathy and frequency of NPDR progresses to proliferative diabetic retinopathy by about 14 percent, and increases every year. [9] To date, few effective treatments have been offered. When it comes to treating sensitive NPDR, pan retinal photocoagulation is the treatment of choice.

Corresponding Author: **Dr Minakshi Mitra** Email: chetona.chetona@gmail.com

This approach, however, will limit the ability to see only and may interfere with other visual skills (such as driving ability); also, the rate of recurrence after treatment remains high. Consequently, the development of NPDR local therapeutic drugs is important to prevent it from progressing to the point where it may have a significant impact on the intelligence of the vision.

The growth factor vascular endothelial growth factor (VEGF), according to some study, is involved in the process of retinal neovascularization. [10,11] Intravitreal injections of anti-VEGF medications have grown into a pre-vitreotomy adjuvant treatment. A new VEGF antibody device, Conbercept (KH902; Chengdu Kanghong Biotechnology Co., Ltd., Sichuan, China), has been created and is currently being tested in clinical studies in the United States and China. 17 Conbercept has been shown to improve a wide range of clinical symptoms, including improved visual acuity (BCVA), central foveal intensity (CFT), and the level of choroidal neovascularization, in previous studies. Diabetes macular edema, age-related macular degeneration serous chorioretinopathy, and proliferative diabetic retinopathy were all treated with Conbercept.

Conbercept, on the other hand, hasn't been identified as a widely utilised NPDR medication. Patients with severe NPDR were included in this retrospective clinical investigation, which looked at the effectiveness of intravitreal conbercept injections in the goal of expanding their clinical treatment options. The Journal of International Medical Research (JIMR) is an open-access, peer-reviewed publication that publishes original research findings from throughout the world.

#### **AIMS AND OBJECTIVES:**

To evaluate the efficacy of intravitreal conbercept injections in non-proliferative diabetic retinopathy.

#### **Patients and treatment approaches**

##### **Patients**

This study was performed on patients with type 2 diabetes, medication-controlled glucose levels, glycosylated haemoglobin levels were less than 10%, and blood pressure was below 160/90 mmHg, respectively. To validate solid NPDR, ocular funduscopy, fundus fluorescein angiography, and optical coherence tomography (OCT) were used. Finally, prior to participating in this study, none of the patients had ever received fundus treatment (e.g., retinal photocoagulation or intravitreal injections of anti-VEGF drugs or hormones). Release conditions include media incompatibility and / or effects of malignant retinal vascular disease, as well as poor image quality due to media uncontrollability.

Patients were given a three-pronged approach to treating conbercept under aseptic conditions: received one intravitreal injection per month for three months, after

which they continued or stopped treatment based on their clinical progress. The reversal was performed when one or more of the following conditions were met: On the other hand, OCT showed that the CFT value exceeded 280  $\mu$ m and that the loss of BCVA was 0.2 logarithm of low resolution angle (logMAR). Therapeutic efficacy was measured using three different markers: BCVA, CFT, hard exudate (HE), and microaneurysm (MA) size.

BCVA was calculated using a standard logarithmic visual acuity chart, and then converted to logMAR units for statistical analysis. A spectral-domain optical coherence tomography (OCT) device was used to diagnose CFT. At the same time, patients with severe NPDR had OCT B-scans, which were used to measure HE position in patients' eyes. Using RetmarkerDR, downloaded, the MA number was automatically screened for OCT images.

#### **Examining the Data Statistical Analysis:**

IBM SPSS statistics for Windows, version 22.0, were used for data analysis (IBM Corporation). Values that mean standard deviations are generated and displayed to represent the distribution of measurement data. The v2 test was hired to test the quality variables, while the paired t-test was used to measure changes in BCVA, CFT, HE, and MAs over time. The findings of this study were reported in the journal Neurology. The difference is considered statistically significant when the p value < 0.05.

#### **Clinical features of patients and baseline data:**

The study included a total of 54 people with NPDR (26 males and 28 females; mean age, 60.1 8.3). 54 eyes were selected from 54 patients, including 30 on the right and 24 on the left. The baseline patient characteristics are shown in Table 1. Initially, the median BCVA was 0.71 0.20 logMAR and the median CFT was 424.26 64.89  $\mu$ m. During the follow-up period, treatment included three retina drugs, with an average dose of 6.12 1.89 injections. [TABLE1]

#### **BCVA Modification:**

The BCVA rate at each follow-up period was significantly different from the baseline value, as shown in Figure 1 and Table 2. (P\*0.001). According to these findings, BCVA significantly improved at 1-, 3-, and 6 months follow-up points compared to baseline value, and remained stable over a 12-month follow-up period.

#### **CFT Modification:**

When compared to the baseline value, the mean (CFT) fell significantly at every follow-up time point (, P 0.001). These findings showed that intravitreal conbercept injection reduced CFT significantly and that the effect was sustained.

**Table 1: Different Parameters and No Of Injections.**

Parameters	
Patients/Eyes (n)	54/54
Sex : M/F	26/28
Eyes (n, left /right)	24/30
Mean Age	60.1
Baseline BCVA	0.71
Baseline CFT	424.6
No. of Injections	6.12

**Table 2: Follow Up For 9 Months.**

	BEFORE TREATMENT	1 Month	3 Months	6 Months	9 Months
N=35	0.71	0.52	0.43	0.41	0.42
T	-	5.06	7.65	8.61	8.12
P	-	<0.001	<0.001	<0.001	<0.001

## DISCUSSION

NPDR is more common than proliferative diabetic retinopathy in people with type 2 diabetes; 2 as a result, it is important to detect and treat NPDR as soon as possible to prevent the development of retinopathy-induced diabetic retinopathy. Patients with NPDR were given intravitreal conbercept injections using a three- prerenata procedure in this study. VEGF has been found to accelerate retinal neovascularization and is considered a contributing factor in diabetic retinopathy pathogenesis. With diabetic retinopathy, anti-VEGF medications have recently become a popular treatment. Anti-VEGF eye injections have been used to treat 22 visually impaired diseases [11]. Diabetes patients with retinopathy, in particular, benefit greatly from this life-saving procedure. Effective drugs have been shown in several trials to effectively bind retinopathy and improve BCVA in people with this condition.

The intravitreal injection of methotrexate reduced chronic diabetic oedema, and 16.6% of patients saw significant improvement in BCVA. Because it improves BCVA in patients with diabetes retinopathy, the ranibizumab intravitreal injection is also considered an effective treatment. 26 In addition, It showed that anti-VEGF treatment may reduce the severity of diabetic retinopathy and that the effect of treatment was higher than pan retinal photocoagulation for at least two years.

## CONCLUSION

In afflicted individuals, intravitreal conbercept injection exhibited a clear and persistent therapeutic effect on NPDR, according to our data. However, a more thorough investigation of the therapeutic mechanism is needed.

## REFERENCES

- Zheng Y, Ley SH and Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. *Nat Rev Endocrinol* 2017; 14: 88–98.
- Sun D, Man W and Zhang L. Roles of insulin resistance, endothelial dysfunction and lifestyle changes in the development of cardiovascular disease in diabetic patients. *Curr Drug Targets* 2017; 18: 1792–1799.
- Flyvbjerg A. The role of the complementsystem in diabetic nephropathy. *Nat Rev Nephrol* 2017; 13: 311–318.
- Ahsan H. Diabetic retinopathy–biomolecules and multiple pathophysiology. *Diabetes Metab Syndr* 2015; 9: 51–54.
- Royle P, Mistry H, Auguste P, et al. Panretinal photocoagulation and other forms of laser treatment and drug therapies for nonproliferative diabetic retinopathy: systematic review and economic evaluation. *Health Technol Assess* 2015; 19: v–xxviii, 1–247.
- Deschler EK, Sun JK and Silva PS. Sideeffects and complications of laser treatment in diabetic retinal disease. *Semin Ophthalmol* 2014; 29: 290–300.
- Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. *Ophthalmology* 2011; 118: 615–625.
- Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. *Ophthalmology* 2010; 117: 1078–1086.e2.
- Grant MB, Afzal A, Spoerri P, et al. The role of growth factors in the pathogenesis of diabetic retinopathy. *Expert Opin Investig Drugs* 2004; 13: 1275–1293.
- Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. *Retina* 2006; 26: 352–354.

11. Falavarjani KG, Golabi S and Modarres M. Intravitreal injection of methotrexate in persistent diabetic macular edema: a 6-month follow-up study. *Graefes Arch Clin Exp Ophthalmol* 2016; 254: 2159–2164.